← Leaderboards
Elizabeth Marion Jaffee
Johns Hopkins University
$29,780,612
Attributed
$32,756,215
Total exposure
24
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$54,899,369 · 27
By mechanism
R01$15,474,272 · 7
P01$15,098,771 · 3
U19$10,897,924 · 6
P50$8,565,441 · 9
P30$4,862,961 · 2
Top collaborators
- Lei Zheng8 shared
- William Reece Burns2 shared
- Linda M S Resar2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Lei Zheng$11,028,048
- Nilofer S. Azad$4,756,559
- Dung T Le$5,608,820
- Patrizio Caturegli$4,739,009
- Daniel A Laheru$1,346,152
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesTumorMalignant NeoplasmsMalignant Neoplasm Of PancreasImmuneClinical TrialsCellsResponseImmunotherapyT-LymphocyteProgramsClinical ResearchResectedImmune ResponseVaccinationTumor AntigensPathway InteractionsBaseNeoplastic CellSignal TransductionMonitorAntigensProteinsPancreatic Ductal Adenocarcinoma
Grant awards (128)
Transforming Human Pancreatic Cancer Into An Immunologic Disease$2,582,338
P01 · FY2025 · CA · contact PI
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial$555,474
R01 · FY2025 · CA · contact PI
Targeting HMGA1 Tumor-Stromal Networks in Pancreatic Carcinogenesis$437,746
R01 · FY2025 · CA
Integration of neo-antigen vaccines and immune checkpoint therapy$391,107
P01 · FY2025 · CA · contact PI
Administrative Core$102,282
P01 · FY2025 · CA · contact PI
Transforming Human Pancreatic Cancer Into An Immunologic Disease$2,453,222
P01 · FY2024 · CA · contact PI
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial$530,360
R01 · FY2024 · CA · contact PI
Targeting HMGA1 Tumor-Stromal Networks in Pancreatic Carcinogenesis$431,561
R01 · FY2024 · CA
Integration of neo-antigen vaccines and immune checkpoint therapy$371,552
P01 · FY2024 · CA · contact PI
Administrative Core$97,167
P01 · FY2024 · CA · contact PI
Transforming Human Pancreatic Cancer Into An Immunologic Disease$2,530,690
P01 · FY2023 · CA · contact PI
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial$552,880
R01 · FY2023 · CA
Integration of neo-antigen vaccines and immune checkpoint therapy$383,285
P01 · FY2023 · CA · contact PI
Administrative Core$100,237
P01 · FY2023 · CA · contact PI
Transforming Human Pancreatic Cancer Into An Immunologic Disease$2,530,688
P01 · FY2022 · CA · contact PI
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial$556,932
R01 · FY2022 · CA
Project 4 :Using TME genetics and immunobiology to drive combination immunotherapies$395,115
P50 · FY2022 · CA · contact PI
Integration of neo-antigen vaccines and immune checkpoint therapy$384,650
P01 · FY2022 · CA · contact PI
Project 2: Neo-antigen Vaccines for Pancreatic and Colorectal Cancers$338,877
P50 · FY2022 · CA · contact PI
Administrative Core$95,826
P01 · FY2022 · CA · contact PI
Transforming Human Pancreatic Cancer Into An Immunologic Disease$2,582,338
P01 · FY2021 · CA · contact PI
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial$581,039
R01 · FY2021 · CA
Project 4 :Using TME genetics and immunobiology to drive combination immunotherapies$402,156
P50 · FY2021 · CA · contact PI
Integration of neo-antigen vaccines and immune checkpoint therapy$391,107
P01 · FY2021 · CA · contact PI
Project 2: Neo-antigen Vaccines for Pancreatic and Colorectal Cancers$341,685
P50 · FY2021 · CA · contact PI
Administrative Core$102,282
P01 · FY2021 · CA · contact PI
Project 4 :Using TME genetics and immunobiology to drive combination immunotherapies$403,612
P50 · FY2020 · CA · contact PI
Project 2: Neo-antigen Vaccines for Pancreatic and Colorectal Cancers$346,165
P50 · FY2020 · CA · contact PI
Reprogramming the pancreatic tumor microenvironment with immunotherapy$590,123
R01 · FY2019 · CA
Project 4 :Using TME genetics and immunobiology to drive combination immunotherapies$395,115
P50 · FY2019 · CA · contact PI
Project 2: Neo-antigen Vaccines for Pancreatic and Colorectal Cancers$338,877
P50 · FY2019 · CA · contact PI
Reprogramming the pancreatic tumor microenvironment with immunotherapy$436,026
R01 · FY2018 · CA
Project 4 :Using TME genetics and immunobiology to drive combination immunotherapies$424,856
P50 · FY2018 · CA · contact PI
Project 2: Neo-antigen Vaccines for Pancreatic and Colorectal Cancers$364,385
P50 · FY2018 · CA · contact PI
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development$765,544
R01 · FY2017 · CA · contact PI
Reprogramming the pancreatic tumor microenvironment with immunotherapy$429,841
R01 · FY2017 · CA
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development$766,774
R01 · FY2016 · CA · contact PI
Reprogramming the pancreatic tumor microenvironment with immunotherapy$424,612
R01 · FY2016 · CA
CELL PROCESSING AND GENE THERAPY$419,512
P30 · FY2016 · CA · contact PI
Tumor Antigens for Individual Signatures and Therapy$314,908
P50 · FY2016 · CA · contact PI
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development$767,979
R01 · FY2015 · CA · contact PI
Reprogramming the pancreatic tumor microenvironment with immunotherapy$424,612
R01 · FY2015 · CA
CELL PROCESSING AND GENE THERAPY$419,512
P30 · FY2015 · CA · contact PI
Tumor Antigens for Individual Signatures and Therapy$339,042
P50 · FY2015 · CA · contact PI
Developmental Fund$102,679
P50 · FY2015 · CA · contact PI
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development$799,422
R01 · FY2014 · CA · contact PI
CELL PROCESSING AND GENE THERAPY$402,611
P30 · FY2014 · CA · contact PI
Tumor Antigens for Individual Signatures and Therapy$336,291
P50 · FY2014 · CA · contact PI
Developmental Fund$108,632
P50 · FY2014 · CA · contact PI
CELL PROCESSING AND GENE THERAPY$392,248
P30 · FY2013 · CA · contact PI
Tumor Antigens for Individual Signatures and Therapy$334,502
P50 · FY2013 · CA · contact PI
Developmental Fund$122,011
P50 · FY2013 · CA · contact PI
CELL PROCESSING AND GENE THERAPY$419,512
P30 · FY2012 · CA · contact PI
Tumor Antigens for Individual Signatures and Therapy$357,758
P50 · FY2012 · CA · contact PI
Tolerance mechanisms regulating the complete HER-2/neu CD+8 T cell repertoire$330,091
R01 · FY2012 · CA · contact PI
Developmental Fund$123,160
P50 · FY2012 · CA · contact PI
Tolerance mechanisms regulating the complete HER-2/neu CD+8 T cell repertoire$330,091
R01 · FY2011 · CA · contact PI
Antigen-Specific Monitoring and Therapy in Pancreatic Cancer$235,249
P50 · FY2011 · CA · contact PI
CELL PROCESSING AND GENE THERAPY$466,051
P30 · FY2010 · CA · contact PI
Tolerance mechanisms regulating the complete HER-2/neu CD+8 T cell repertoire$340,300
R01 · FY2010 · CA · contact PI
Combinatorial Vaccine Approaches for the treatment of BC$315,989
P50 · FY2010 · CA · contact PI
Antigen-Specific Monitoring and Therapy in Pancreatic Cancer$246,538
P50 · FY2010 · CA · contact PI
Combinational Immunotherapies to Amplify Vaccine Induced Immunity$1,106,675
U19 · FY2009 · CA · contact PI
CELL PROCESSING AND GENE THERAPY$472,459
P30 · FY2009 · CA · contact PI
Combinatorial Vaccine Approaches for the treatment of BC$344,921
P50 · FY2009 · CA · contact PI
Tolerance mechanisms regulating the complete HER-2/neu CD+8 T cell repertoire$340,300
R01 · FY2009 · CA · contact PI
Antigen-Specific Monitoring and Therapy in Pancreatic Cancer$245,567
P50 · FY2009 · CA · contact PI
PANCREAS CANCER MESOTHELIN ANIMAL MODEL$231,233
U19 · FY2009 · CA · contact PI
CELL PROCESSING AND GENE THERAPY$186,271
P30 · FY2009 · CA · contact PI
CORE--CELL$98,711
U19 · FY2009 · CA · contact PI
Combinational Immunotherapies to Amplify Vaccine Induced Immunity$1,110,621
U19 · FY2008 · CA · contact PI
Tolerance mechanisms regulating the complete HER-2/neu CD+8 T cell repertoire$340,300
R01 · FY2008 · CA · contact PI
Antigen-Specific Monitoring and Therapy in Pancreatic Cancer$243,788
P50 · FY2008 · CA · contact PI
PANCREAS CANCER MESOTHELIN ANIMAL MODEL$232,231
U19 · FY2008 · CA · contact PI
CELL PROCESSING AND GENE THERAPY$227,723
P30 · FY2008 · CA · contact PI
Combinatorial Vaccine Approaches for the treatment of BC$198,431
P50 · FY2008 · CA · contact PI
CORE--CELL$100,068
U19 · FY2008 · CA · contact PI
Combinational Immunotherapies to Amplify Vaccine Induced Immunity$1,135,847
U19 · FY2007 · CA · contact PI
PANCREAS CANCER MESOTHELIN ANIMAL MODEL$237,696
U19 · FY2007 · CA · contact PI
Antigen-Specific Monitoring and Therapy in Pancreatic Cancer$229,109
P50 · FY2007 · CA · contact PI
CELL PROCESSING AND GENE THERAPY$227,723
P30 · FY2007 · CA · contact PI
Combinatorial Vaccine Approaches for the treatment of BC$198,431
P50 · FY2007 · CA · contact PI
CORE--CELL$103,230
U19 · FY2007 · CA · contact PI
Combinational Immunotherapies to Amplify Vaccine Induce*$1,169,956
U19 · FY2006 · CA · contact PI
CELL PROCESSING AND GENE THERAPY$227,723
P30 · FY2006 · CA · contact PI
Combinatorial Vaccine Approaches for the treatment of BC$198,431
P50 · FY2006 · CA · contact PI
PANCREAS CANCER MESOTHELIN ANIMAL MODEL$149,706
U19 · FY2006 · CA · contact PI
CORE--CELL$65,478
U19 · FY2006 · CA · contact PI
Combinational Immunotherapies to Amplify Vaccine Induced$1,193,000
U19 · FY2005 · CA
Chemotherapy plus vaccine for metastatic breast cancer$438,356
R01 · FY2005 · CA
PANCREAS CANCER MESOTHELIN ANIMAL MODEL$149,810
U19 · FY2005 · CA
CORE--CELL$65,883
U19 · FY2005 · CA
Chemotherapy plus vaccine for metastatic breast cancer$429,983
R01 · FY2004 · CA
IDENTIFICATION OF CD8+ T CELL TARGETS ON RENAL CANCER$288,736
R01 · FY2004 · CA
ANTIGEN-SPECIFIC VACCINES FOR BREAST CANCER$1,055,613
U19 · FY2003 · CA
Chemotherapy plus vaccine for metastatic breast cancer$433,408
R01 · FY2003 · CA
ALLOGENIC PANCREATIC TUMOR VACCINE CELL LINE$398,129
R01 · FY2003 · CA
IDENTIFICATION OF CD8+ T CELL TARGETS ON RENAL CANCER$280,922
R01 · FY2003 · CA
ANTIGEN-SPECIFIC VACCINES FOR BREAST CANCER$1,030,900
U19 · FY2002 · CA
Chemotherapy plus vaccine for metastatic breast cancer$467,494
R01 · FY2002 · CA
ALLOGENIC PANCREATIC TUMOR VACCINE CELL LINE$395,000
R01 · FY2002 · CA
IDENTIFICATION OF CD8+ T CELL TARGETS ON RENAL CANCER$272,743
R01 · FY2002 · CA
Core--Cell Processing and Gene Therapy Facility$250,404
P30 · FY2002 · CA
Core--Cell Processing and Gene Therapy Facility$250,404
P30 · FY2002 · CA
CORE--ANIMAL$0
U19 · FY2002 · CA
VACCINES--A NEW PARADIGM FOR BREAST CANCER$0
P50 · FY2002 · CA
Chemotherapy with Vaccination in Metastatic Pancreatic C$0
P50 · FY2002 · CA
IDENTIFICATION OF T CELL RECOGNITION TARGETS ON PANCREATIC ADENOCARCINOMA$0
P50 · FY2002 · CA
SYNERGISTIC CHEMOTHERAPY HER2/NEU VACCINES--BREAST CANCE$0
U19 · FY2002 · CA
ANTIGEN-SPECIFIC VACCINES FOR BREAST CANCER$1,001,273
U19 · FY2001 · CA
ALLOGENIC PANCREATIC TUMOR VACCINE CELL LINE$406,745
R01 · FY2001 · CA
IDENTIFICATION OF CD8+ T CELL TARGETS ON RENAL CANCER$265,203
R01 · FY2001 · CA
Core--Cell Processing and Gene Therapy Facility$250,404
P30 · FY2001 · CA
Core--Cell Processing and Gene Therapy Facility$250,404
P30 · FY2001 · CA
CORE--ANIMAL$0
U19 · FY2001 · CA
VACCINES--A NEW PARADIGM FOR BREAST CANCER$0
P50 · FY2001 · CA
IDENTIFICATION OF T CELL RECOGNITION TARGETS ON PANCREATIC ADENOCARCINOMA$0
P50 · FY2001 · CA
IDENTIFICATION OF T CELL RECOGNITION TARGETS ON PANCREATIC ADENOCARCINOMA$0
P50 · FY2001 · CA
IDENTIFICATION OF T CELL RECOGNITION TARGETS ON PANCREATIC ADENOCARCINOMA$0
P50 · FY2001 · CA
Core--Cell Processing and Gene Therapy Facility$0
P30 · FY2001 · CA
SYNERGISTIC CHEMOTHERAPY HER2/NEU VACCINES--BREAST CANCE$0
U19 · FY2001 · CA
ANTIGEN-SPECIFIC VACCINES FOR BREAST CANCER$659,993
U19 · FY2000 · CA
ALLOGENIC PANCREATIC TUMOR VACCINE CELL LINE$399,791
R01 · FY2000 · CA
IDENTIFICATION OF CD8+ T CELL TARGETS ON RENAL CANCER$265,755
R01 · FY2000 · CA
IDENTIFICATION OF T CELL RECOGNITION TARGETS ON PANCREATIC ADENOCARCINOMA$219,161
P50 · FY2000 · CA
SYNERGISTIC CHEMOTHERAPY HER2/NEU VACCINES--BREAST CANCE$0
U19 · FY2000 · CA
CORE--ANIMAL$0
U19 · FY2000 · CA
VACCINES--A NEW PARADIGM FOR BREAST CANCER$0
P50 · FY2000 · CA